GlassScriptPhysician profile
Joseph Zaladonis
NPI 1013949346
$7,525.40
in general payments reported to CMS, 2019-2025
28 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,556 · 2020: $178 · 2021: $284 · 2022: $1,570 · 2023: $1,035 · 2024: $1,384 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,516 · Education: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,516.07 |
| Education | $420.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,246.49 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $783.75 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $701.54 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $584.18 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $467.28 | 2022-2024 | Sotyktu |
| Merz North America, INC. | $349.74 | 2019 | |
| Leo Pharma INC. | $323.59 | 2019-2025 | Anzupgo, Adbry |
| Janssen Scientific Affairs, LLC | $271.26 | 2019-2022 | |
| Galderma Laboratories, L.P. | $264.94 | 2019-2025 | Nemluvio |
| Pfizer INC. | $226.22 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $224.64 | 2020-2025 | Ilumya |
| Ucb, INC. | $205.10 | 2020-2024 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $132.18 | 2024-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Incyte Corporation | $93.79 | 2022-2025 | Opzelura |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $83.95 | 2021 | |
| Arcutis Biotherapeutics, INC. | $79.38 | 2025 | Zoryve |
| Mayne Pharma Commercial LLC | $60.79 | 2019-2024 | |
| Organon LLC | $55.09 | 2024-2025 | Vtama, Hadlima |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.66 | 2019-2020 | |
| Dermavant Sciences, INC. | $45.93 | 2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $43.27 | 2020-2025 | |
| Botanix Sb INC | $35.11 | 2025 | Sofdra |
| Amgen INC. | $31.77 | 2023-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.02 | 2023 | Spevigo |
| Epi Health, LLC | $20.35 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.17 | 2019 | |
| Prugen, INC. Pharmaceuticals | $7.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Zaladonis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.